CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
ropinirole controlled release (CR)-RLSdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00530790
NCT00530790Phase 2Completed
CompareCT.gov

Clinical Evaluation of Ropinirole CR-RLS Tablets in Restless Legs Syndrome-Open-Label, Uncontrolled Study. Classification: Clinical Pharmacology, Exploratory

GlaxoSmithKline·interventional·Posted Sep 17, 2007·Updated Sep 26, 2018

In Brief

A Phase 2 clinical trial evaluating ropinirole controlled release (CR)-RLS for Restless Legs Syndrome. Completed, enrolled 35 participants across 11 sites.

Detailed Summary

This study was designed to evaluate the safety, pharmacokinetic profile and efficacy in Restless Legs Syndrome patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRestless Legs Syndrome
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 17, 2007
Enrollment StartAug 23, 2007
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 18.8 years ago

Interventions

ropinirole controlled release (CR)-RLSdrug

White film-coated round-shaped tablet